title: Efficacy of a recombinant glycoprotein D subunit vaccine on the development of primary and recurrent ocular infection with herpes simplex virus type 1 in mice.
abstract: The protective efficacy of a glycoprotein D subunit vaccine (gD2 SB AS4) was evaluated in a mouse model of human recurrent herpetic stromal keratitis (HSK). When administered before primary infection, gD2 SB AS4 protected mice against corneal pathology, mortality, and latency resulting from ocular viral challenge with herpes simplex virus type 1 (HSV-1) McKrae strain. In addition, gD2 SB AS4 significantly decreased postreactivation corneal disease. A control vaccine, gD2 alum, protected against acute ocular infection only. When administered after primary infection, gD2 SB AS4 vaccination decreased postreactivation ocular shedding but had no other significant effects. Vaccination with gD2 SB AS4 was associated with high anti-gD antibody responses and low delayed-type hypersensitivity responses. These results have identified a prophylactic vaccine, gD2 SB AS4, with activity against acute and recurrent HSK in mice and emphasize the need for vaccine evaluation in both primary and recurrent ocular herpetic disease models.
authors.affiliation: Department of Ophthalmology and Visual Sciences, Washington University School of Medicine, St. Louis, Missouri 63110, USA.
authors.forename: T L
authors.initials: TL
authors.lastname: Keadle
authors.forename: K A
authors.initials: KA
authors.lastname: Laycock
authors.forename: J K
authors.initials: JK
authors.lastname: Miller
authors.forename: K K
authors.initials: KK
authors.lastname: Hook
authors.forename: E D
authors.initials: ED
authors.lastname: Fenoglio
authors.forename: M
authors.initials: M
authors.lastname: Francotte
authors.forename: M
authors.initials: M
authors.lastname: Slaoui
authors.forename: P M
authors.initials: PM
authors.lastname: Stuart
authors.forename: J S
authors.initials: JS
authors.lastname: Pepose
mesh_terms: D000818:Animals; D000914:Antibodies, Viral / Q000097:blood; D003315:Cornea / Q000473:pathology; D004195:Disease Models, Animal; D005260:Female; D018259:Herpesvirus 1, Human / Q000276:immunology* / Q000302:isolation & purification; D022283:Herpesvirus Vaccines; D006801:Humans; D006968:Hypersensitivity, Delayed; D016849:Keratitis, Herpetic / Q000401:mortality / Q000517:prevention & control* / Q000628:therapy* / Q000821:virology; D051379:Mice; D008815:Mice, Inbred Strains; D012008:Recurrence; D013666:Tears / Q000821:virology; D012668:Trigeminal Ganglion / Q000821:virology; D014611:Vaccination; D014614:Vaccines, Synthetic / Q000627:therapeutic use; D014759:Viral Envelope Proteins / Q000276:immunology*; D014765:Viral Vaccines / Q000627:therapeutic use; D017735:Virus Latency; D017201:Virus Shedding
chemical_list: D000914:Antibodies, Viral; D022283:Herpesvirus Vaccines; D014614:Vaccines, Synthetic; D014759:Viral Envelope Proteins; D014765:Viral Vaccines; C039447:glycoprotein D, Human herpesvirus 1; C069093:herpes simplex virus-1 glycoprotein D vaccine